Verastem

Verastem Oncology is a biotechnology company focused on developing medicines that target cancer stem cells—cells that can drive tumor growth and resistance to treatment. Their approach aims to improve cancer therapy effectiveness by specifically inhibiting these resilient cells, thereby reducing the chances of relapse and improving patient outcomes. The company's main focus is on developing drugs, such as VS-6766 and defactinib, to treat solid tumors like ovarian and pancreatic cancers. Overall, Verastem works on innovative cancer treatments that address the root of tumor persistence, aiming to offer more durable and effective solutions for patients.